Targeting the PSGL-1 Immune Checkpoint Promotes Immunity to PD-1-Resistant Melanoma

Area of Science:

• Immunology
• Oncology
• Cancer Research

Background:

• Immune-checkpoint inhibitors (ICIs) show promise in cancer treatment by enhancing antitumor immune responses.
• However, a significant portion of patients do not respond to current ICI therapies, necessitating the development of novel therapeutic strategies.
• P-selectin glycoprotein ligand-1 (PSGL-1) is known to suppress immune responses, but its therapeutic potential in cancer immunity remains largely unexplored.

Purpose of the Study:

• To investigate the therapeutic potential of targeting PSGL-1 to enhance antitumor immunity.
• To evaluate the efficacy of PSGL-1 blockade, alone and in combination with PD-1 inhibition, in a preclinical melanoma model.

Main Methods:

• Utilized an aggressive melanoma tumor model in mice.
• Administered anti-PSGL-1 therapy to tumor-bearing mice.
• Assessed T-cell responses (CD4+, CD8+, regulatory T cells), T-cell function, and tumor growth kinetics.
• Investigated the combination of anti-PSGL-1 and anti-PD-1 therapies in both wild-type and PSGL-1-deficient mice.

Main Results:

• Targeting PSGL-1 increased effector CD4+ and CD8+ T-cell responses and reduced regulatory T cells within tumors.
• Anti-PSGL-1 treatment enhanced T-cell effector function, activation, and proliferation, leading to delayed tumor growth.
• Combined PSGL-1 and PD-1 blockade significantly enhanced antitumor immunity and slowed melanoma progression.
• In PSGL-1-deficient mice, PD-1 targeting resulted in a higher frequency of complete tumor eradication.

Conclusions:

• Therapeutic targeting of the PSGL-1 immune checkpoint can reinvigorate antitumor immunity.
• PSGL-1 blockade demonstrates potential as a novel therapeutic strategy for enhancing cancer treatment outcomes.
• Combination therapy involving PSGL-1 and PD-1 inhibition shows synergistic effects in promoting antitumor responses.